Nerissa Kreher Leaves Avrobio for Tiburio Chief Medical Officer Post

Tiburio Therapeutics has appointed Nerissa Kreher to the newly created position of chief medical officer. Kreher held that post at her previous company, Avrobio (NASDAQ: [[ticker:AVRO]]). Her experience also includes positions at Shire, Zafgen (NASDAQ: [[ticker:ZFGN]]), and Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]). In January, Tibiurio launched from biotech accelerator Cydan, backed by $31 million in funding. Cambridge, MA-based Tiburio is developing treatments for rare neuroendocrine tumors and rare endocrine diseases.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.